However, with the nanotechnology now widely used to deliver COVID-19 spike protein mRNA into vaccines, it is now feasible to use the similar strategy to deliver aptamers against HER2 into HER2 + breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.